Merus News Releases https://ir.merus.nl/ Merus News Releases en Merus to Present at the Jefferies 2019 Healthcare Conference https://ir.merus.nl/news-releases/news-release-details/merus-present-jefferies-2019-healthcare-conference UTRECHT, Netherlands , June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Mon, 03 Jun 2019 08:28:00 -0400 Merus News Releases 7916 Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-first-quarter-2019-and UTRECHT, The Netherlands , May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the Thu, 30 May 2019 16:05:00 -0400 Merus News Releases 7901 Merus Announces 2019 Annual General Meeting of Shareholders https://ir.merus.nl/news-releases/news-release-details/merus-announces-2019-annual-general-meeting-shareholders UTRECHT, The Netherlands , May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Thu, 23 May 2019 08:00:00 -0400 Merus News Releases 7891 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference https://ir.merus.nl/news-releases/news-release-details/merus-present-rbc-capital-markets-2019-healthcare-conference UTRECHT, Netherlands , May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Mon, 20 May 2019 08:38:00 -0400 Merus News Releases 7846 Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors https://ir.merus.nl/news-releases/news-release-details/merus-announces-first-patient-treated-phase-1-clinical-trial UTRECHT, Netherlands , May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating Thu, 09 May 2019 08:00:00 -0400 Merus News Releases 7841 Merus Announces Financial Results for the Full Year 2018 and Provides Business Update https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-full-year-2018-and-provides Multiple Updates from Biclonics® Clinical Trials Expected in 2019 UTRECHT, The Netherlands , April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human Wed, 03 Apr 2019 16:00:00 -0400 Merus News Releases 7791 Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 https://ir.merus.nl/news-releases/news-release-details/merus-and-incyte-present-mcla-145-program-preclinical-data-aacr CD137 and PD-L1 bispecific antibody with context-dependent T cell activation UTRECHT, Netherlands , April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human Mon, 01 Apr 2019 07:00:00 -0400 Merus News Releases 7776 Merus to Present at the Cowen & Co. 39th Annual Health Care Conference https://ir.merus.nl/news-releases/news-release-details/merus-present-cowen-co-39th-annual-health-care-conference UTRECHT, Netherlands , March 11, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Mon, 11 Mar 2019 04:09:00 -0400 Merus News Releases 7741 Merus to Participate in Guggenheim Healthcare Talks Idea Forum https://ir.merus.nl/news-releases/news-release-details/merus-participate-guggenheim-healthcare-talks-idea-forum UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Thu, 07 Feb 2019 07:00:00 -0500 Merus News Releases 7686 Merus Announces IND Clearance for MCLA-145 https://ir.merus.nl/news-releases/news-release-details/merus-announces-ind-clearance-mcla-145 MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today Mon, 07 Jan 2019 08:00:00 +0100 Merus News Releases 7546